These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 17244174)

  • 21. Combined treatment with amisulpride in patients with schizophrenia discharged from a short-term hospitalization unit: a 1-year retrospective study.
    Molina JD; Lerma-Carrillo I; Leonor M; Pascual F; Blasco-Fontecilla H; González-Parra S; López-Muñoz F; Alamo C
    Clin Neuropharmacol; 2009; 32(1):10-5. PubMed ID: 18978498
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quality of life and its association with insight, adverse effects of medication and use of atypical antipsychotics in patients with bipolar disorder and schizophrenia in remission.
    Yen CF; Cheng CP; Huang CF; Yen JY; Ko CH; Chen CS
    Bipolar Disord; 2008 Jul; 10(5):617-24. PubMed ID: 18657246
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence of remission and recovery in schizophrenia in the Czech Republic.
    Prikryl R; Kholova M; Kucerova HP; Ceskova E
    Compr Psychiatry; 2013 Oct; 54(7):1111-6. PubMed ID: 23810077
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Changes in neurocognitive function in patients with schizophrenia after starting or switching to amisulpride in comparison with the normal controls.
    Ahn YM; Lee KY; Kim CE; Kim JJ; Kang DY; Jun TY; Choi JS; Chung IW; Kim SH; Hwang SS; Kim YS
    J Clin Psychopharmacol; 2009 Apr; 29(2):117-23. PubMed ID: 19512972
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term patterns of subjective wellbeing in schizophrenia: cluster, predictors of cluster affiliation, and their relation to recovery criteria in 2842 patients followed over 3 years.
    Lambert M; Schimmelmann BG; Schacht A; Karow A; Wagner T; Wehmeier PM; Huber CG; Hundemer HP; Dittmann RW; Naber D
    Schizophr Res; 2009 Feb; 107(2-3):165-72. PubMed ID: 18842393
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Psychopharmacotherapy and remission of patients with schizophrenia.
    Degmecić D; Pozgain I; Filaković P; Dodig-Curković K; Mihanović M
    Coll Antropol; 2009 Jun; 33(2):547-51. PubMed ID: 19662777
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical predictors of therapeutic response to clozapine in a sample of Turkish patients with treatment-resistant schizophrenia.
    Semiz UB; Cetin M; Basoglu C; Ebrinc S; Uzun O; Herken H; Balibey H; Algul A; Ates A
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Aug; 31(6):1330-6. PubMed ID: 17618026
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Is it true remission? A study of remitted patients affected by schizophrenia and schizoaffective disorders.
    Pinna F; Deriu L; Lepori T; Maccioni R; Milia P; Sarritzu E; Tusconi M; Carpiniello B;
    Psychiatry Res; 2013 Dec; 210(3):739-44. PubMed ID: 24007858
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Response and remission of subjective well-being in patients suffering from schizophrenia spectrum disorders.
    Schennach-Wolff R; Seemüller F; Obermeier M; Messer T; Laux G; Pfeiffer H; Naber D; Schmidt LG; Gaebel W; Klosterkötter J; Heuser I; Maier W; Lemke MR; Rüther E; Buchkremer G; Gastpar M; Jäger M; Möller HJ; Riedel M
    Eur Psychiatry; 2011; 26(5):284-92. PubMed ID: 20435447
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An open, randomized, comparative study of efficacy and safety of risperidone and haloperidol in schizophrenia.
    Tamrakar SM; Nepal MK; Koirala NR; Sharma VD; Gurung CK; Adhikari SR
    Kathmandu Univ Med J (KUMJ); 2006; 4(2):152-60. PubMed ID: 18603890
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neurocognitive and clinical predictors of functional outcome in patients with schizophrenia and bipolar I disorder at one-year follow-up.
    Tabarés-Seisdedos R; Balanzá-Martínez V; Sánchez-Moreno J; Martinez-Aran A; Salazar-Fraile J; Selva-Vera G; Rubio C; Mata I; Gómez-Beneyto M; Vieta E
    J Affect Disord; 2008 Aug; 109(3):286-99. PubMed ID: 18289698
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Int Clin Psychopharmacol; 2008 Nov; 23(6):325-31. PubMed ID: 18854720
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Amisulpride doses and plasma levels in different age groups of patients with schizophrenia or schizoaffective disorder.
    Müller MJ; Eich FX; Regenbogen B; Sachse J; Härtter S; Hiemke C
    J Psychopharmacol; 2009 May; 23(3):278-86. PubMed ID: 18562411
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prediction of the significance in the improvement of depression symptoms of amisulpride in the treatment of schizophrenia: an 8-week case-control study.
    Wang G; Zhou B; Zheng L; Ni Y; Pan A
    Ann Palliat Med; 2020 Sep; 9(5):3481-3487. PubMed ID: 33065798
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prediction of remission as a combination of symptomatic and functional remission and adequate subjective well-being in 2960 patients with schizophrenia.
    Lambert M; Schimmelmann BG; Naber D; Schacht A; Karow A; Wagner T; Czekalla J
    J Clin Psychiatry; 2006 Nov; 67(11):1690-7. PubMed ID: 17196047
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rates and predictors of remission and recovery during 3 years in 392 never-treated patients with schizophrenia.
    Lambert M; Naber D; Schacht A; Wagner T; Hundemer HP; Karow A; Huber CG; Suarez D; Haro JM; Novick D; Dittmann RW; Schimmelmann BG
    Acta Psychiatr Scand; 2008 Sep; 118(3):220-9. PubMed ID: 18699954
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Remitted but still impaired? Symptomatic versus functional remission in patients with schizophrenia.
    Karow A; Moritz S; Lambert M; Schöttle D; Naber D;
    Eur Psychiatry; 2012 Aug; 27(6):401-5. PubMed ID: 21570262
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Remission, prediction and stability of symptoms in schizophrenia: A naturalistic 12-month follow-up study.
    Wolter A; Wolfgang Preuss U; Richard Krischke N; Mooi Wong W; Zimmermann J
    Int J Psychiatry Clin Pract; 2010 Sep; 14(3):160-7. PubMed ID: 24917315
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prediction of Self-Report Cognitive Function for the Symptomatic Remission in Schizophrenia Treated with Amisulpride: a Multicenter, 8-Week Case-Control Study.
    Ji JW; Liu LY; Hao KR; Yu YL; Weng SZ; Wu JF; Huang RC
    Psychiatr Q; 2021 Sep; 92(3):935-945. PubMed ID: 33389476
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Correlates of subjective well-being in schizophrenic patients treated with atypical antipsychotics.
    Schimmelmann BG; Moritz S; Karow A; Schafer I; Bussopulos A; Golks D; Krausz M; Naber D; Lambert M
    Int J Psychiatry Clin Pract; 2005; 9(2):94-8. PubMed ID: 24930789
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.